MedTrace Logo

CSTC1 for Diabetic Foot Ulcers Phase II Study

NCT01813305 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2022-04-12

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with diabetic foot ulcers.

Conditions

Interventions

DRUG

CSTC1

vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof

DRUG

CSTC1 Matched vehicle

Sponsors & Collaborators

  • ASKLEP Inc.

    collaborator INDUSTRY

  • Charsire Biotechnology Corp.

    lead INDUSTRY

Principal Investigators

  • Su-Shin Lee, MD · Kaohsiung Medical University Chung-Ho Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-09
Primary Completion
2020-01-07
Completion
2020-01-07

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01813305 on ClinicalTrials.gov